Ardelyx irritable bowel syndrome drug succeeds in mid-stage trial

Oct 1 (Reuters) - Ardelyx Inc said its experimental drug to treat constipation-related irritable bowel syndrome achieved the main goal of increasing bowel movement compared to a placebo in a mid-stage study involving 371 patients.